Sartorius Stedim Biotech SA: Information on Document Availability
|
Sartorius Stedim Biotech SA
Aubagne, February 17, 2023
Sartorius Stedim Biotech: Information on Document Availability
Sartorius Stedim Biotech Group’s Universal Registration Document 2022 is now available at:
It contains the following information: - Business development for fiscal 2022 and the 2023 forecast for the Sartorius Stedim Biotech Group - Consolidated financial statements for the year ended December 31, 2022
A profile of Sartorius Stedim BiotechSartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, the shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2022, the company employed roughly 12,000 people, and earned sales revenue of around 3.5 billion euros.
Phone: +49(0)551.308.1686; [email protected]
Follow Sartorius Stedim Biotech on Twitter @Sartorius_Group and on LinkedIn.
Regulatory filing PDF file File: Sartorius Stedim Biotech S.A. - Information on Document Availability |
| Language: | English |
| Company: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | [email protected] |
| Internet: | www.sartorius-stedim.com |
| ISIN: | FR0013154002 |
| Euronext Ticker: | DIM |
| AMF Category: | Annual financial and audit reports / Terms of availability of the annual financial report |
| EQS News ID: | 1562307 |
| End of Announcement | EQS News Service |
1562307 17-Feb-2023 CET/CEST
